PHVS · Pharvaris N.V.
$38.02
+1.36% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-13.9
Dividend yield
—
Beta
-2.32
Avg volume
1M
Employees
0K
Daily Change %
1.36%
5 Days Change
7.06%
10 Days Change
9.04%
30 Days Change
9.65%
60 Days Change
7.61%
Month to Day Change
8.04%
Year to Day Change
36.00%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PHVS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
Morgan Stanley
Overweight$62.00
+65.3% vs priceWells Fargo
Overweight$65.00
+73.3% vs priceRBC Capital
Outperform$62.00
+65.3% vs priceBank of America
Neutral$30.00
-20.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Guggenheim | Maintains | Buy | $40.00 → $44.00 |
| 2026-09-09 | Morgan Stanley | Maintains | Overweight | $46.00 → $62.00 |
| 2026-09-09 | Leerink Partners | Maintains | Outperform | $50.00 → $65.00 |
| 2026-09-09 | Wells Fargo | Maintains | Overweight | $55.00 → $65.00 |
| 2026-09-09 | RBC Capital | Maintains | Outperform | $52.00 → $62.00 |
| 2026-09-09 | Citizens | Maintains | Market Outperform | $75.00 → $79.00 |
| 2026-09-09 | Wedbush | Maintains | Outperform | $42.00 → $50.00 |
| 2026-09-08 | HC Wainwright & Co. | Reiterates | Buy | $60.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 8.4% above the 50-day MA ($35.06).
- Price vs 200-day MA: Trading 27.6% above the 200-day MA ($29.80).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.15) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($38.02).
PHVS Price Chart
Loading chart for PHVS…
Fundamentals
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.